CSCIF — COSCIENS Biopharma Income Statement
0.000.00%
Last trade - 00:00- $6.56m
- $1.40m
- $7.50m
Annual income statement for COSCIENS Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.26 | 5.64 | 7.14 | 9.59 | 7.5 |
| Cost of Revenue | |||||
| Gross Profit | 5.17 | 5.48 | 2.94 | 4.73 | 2.65 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 13.9 | 29.2 | 11.8 | 27.9 | 18.2 |
| Operating Profit | -8.67 | -23.6 | -4.63 | -18.3 | -10.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.48 | -22.7 | -4.37 | -15.2 | -10.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.37 | -22.7 | -3.48 | -15.3 | -10.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.37 | -22.7 | -3.48 | -15.3 | -10.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.37 | -22.7 | -3.48 | -15.3 | -10.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.28 | -11.8 | -1.89 | -4.86 | -3.21 |